Nivolumab Alone or With Ipilimumab Provides Durable Benefit in MSI-H/dMMR mCRC
Data from the CheckMate-142 study support the use of nivolumab (Opdivo) alone or in combination ipilimumab (Yervoy) for the treatment of patients with previously treated DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.
Source: OncLive